Larimar Therapeutics Inc. (LRMR)
NASDAQ: LRMR
· Real-Time Price · USD
4.00
-0.26 (-6.10%)
At close: Aug 15, 2025, 3:59 PM
4.02
0.63%
After-hours: Aug 15, 2025, 07:34 PM EDT
Larimar Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -95.23M | -80.6M | -64.77M | -58.34M | -45.08M | -36.95M | -33.38M | -32.64M | -32.94M | -35.35M | -35.06M | -43.55M | -47.49M | -50.64M | -55.71M | -49.17M | -47.9M |
Depreciation & Amortization | -429K | 318K | 322K | 324K | 313K | 311K | 308K | 309K | 314K | 318K | 328K | 339K | 335K | 326K | 288K | 250K | 205K |
Stock-Based Compensation | 8.5M | 8.8M | 8.3M | 8.17M | 7.91M | 7.62M | 7.34M | 7.18M | 6.82M | 6.62M | 6.46M | 6.25M | 5.93M | 5.47M | 5M | 3.91M | 3.31M |
Other Working Capital | 2.66M | 5.03M | 1.79M | 10.02M | 1.57M | 188K | -724K | -433K | 3.6M | 1.64M | 521K | 2.58M | 3.69M | 3.72M | 6.36M | 3.41M | 90K |
Other Non-Cash Items | -2.11M | -2.31M | -173K | 1.58M | 2.23M | 222K | -1.43M | -1.48M | -1.46M | -825K | -73K | -17K | -15K | -15K | -14K | 4K | 4.24K |
Deferred Income Tax | n/a | n/a | -1.55M | -2.12M | -2.15M | -2.15M | -594K | -29K | n/a | 5K | 5K | 5K | 5K | n/a | n/a | n/a | n/a |
Change in Working Capital | 3.51M | 6.17M | 2.72M | 10.58M | 2.45M | -2.51M | -3.03M | -810K | -320K | 1.67M | -467K | 1.83M | 2.81M | 2.75M | 6.38M | 1.94M | -110K |
Operating Cash Flow | -86.89M | -70.76M | -58.29M | -42.94M | -36.32M | -33.46M | -30.79M | -27.47M | -27.59M | -27.57M | -28.82M | -35.14M | -38.43M | -42.1M | -44.04M | -43.07M | -44.48M |
Capital Expenditures | -564K | -515K | -500K | -438K | -164K | -164K | n/a | n/a | -100K | -100K | -109K | -402K | -333K | -333K | -325K | -37K | -6K |
Cash Acquisitions | n/a | n/a | 2.46K | 2.46K | 2.46K | 2.46K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -60K | -63K | -576K |
Purchase of Investments | -195.51M | -227.87M | -224.21M | -257.97M | -186.1M | -101.23M | -138.25M | -108.22M | -133.61M | -133.61M | -61.63M | -41.74M | -6.5M | -8.25M | -32.73M | -26.23M | -26.23M |
Sales Maturities Of Investments | 193.5M | 143M | 117.5M | 77.49M | 59M | 134.75M | 122M | 135.01M | 135M | 42.75M | 29.5M | 6.5M | 25.75M | 32.75M | 27.25M | 27.25M | 8M |
Other Investing Acitivies | -63.22M | -131.58M | -131.58M | -131.63M | -68.42M | 33.52K | -16.25K | 26.79K | 1.39K | -90.86K | -32.13K | -35.24K | 19.25K | 24.5K | 20K | 26.5K | 41.94M |
Investing Cash Flow | -2.58M | -85.39M | -107.21M | -180.91M | -127.26M | 33.35M | -16.25M | 26.79M | 1.29M | -90.96M | -32.24M | -35.64M | 18.92M | 24.17M | -5.87M | 917K | 23.12M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | 334K | 334K | 334K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 41K | 41K | 41K | 41K | 30K | 30K | 30K | 75.57M | 75.57M | 75.57M | 75.57M | n/a | n/a | n/a | n/a | n/a | 83.9M |
Financial Cash Flow | -268K | 161.88M | 161.85M | 161.85M | 162.18M | 30K | -286K | 75.26M | 75.26M | 75.26M | 75.57M | 19.89M | 19.89M | 19.89M | 20.13M | 107K | 84.01M |
Net Cash Flow | -88.39M | 7.08M | -2.31M | -62.01M | -1.4M | -76K | -47.33M | 74.58M | 48.96M | -43.27M | 14.52M | -50.89M | 371K | 1.95M | -29.78M | -42.04M | 62.65M |
Free Cash Flow | -87.45M | -71.28M | -58.79M | -43.38M | -36.48M | -33.62M | -30.79M | -27.47M | -27.69M | -27.67M | -28.92M | -35.54M | -38.77M | -42.44M | -44.37M | -43.1M | -44.49M |